BriaCell Therapeutics Corp. (BCTXW)

Market Cap	15.11M
Revenue (ttm)	n/a
Net Income (ttm)	-11.59M
Shares Out	3.71M
EPS (ttm)	-6.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,722
Open	0.1030
Previous Close	0.1125
Day's Range	0.1030 - 0.1030
52-Week Range	0.0799 - 0.0948
Beta	1.71
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About BCTXW

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. I...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: William Williams
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCTXW
• Website: https://briacell.com